Hong Kong Stock Market Dynamics | Rongchang Bioscience (09995.HK) Soars Over 5% Again, Vedolizumab Monoclonal Antibody Phase III Clinical Trial Achieves Primary Endpoint, Company to Submit New Drug Application for Listing at an Opportune Time
According to the "CCStock" app, Rongchang Bio (09995.HK) has risen by over 5% again, as of the time of publication, it has risen by 3.7%, reaching HK$40.65, with a turnover of HK$1.1 billion.
Latest
